Refine by
Medication Management Articles & Analysis
175 news found
“While there is no cure for asthma, it can be managed with medical treatment and by avoiding exposure to asthma triggers,” said Harry Pena, President of Zimmetry Environmental. ...
MedSource Labs Moves the Needle in the Peripheral Safety IV Market With the announcement of ClearSafe Comfort® and TrueSafe Comfort® Blood Control IV Catheters with groundbreaking active check valve ...
Proprietary data and software from both platforms will be used to create novel AI-based applications to improve the entire surgical continuum, including medical billing, patient pathway management, and revenue assurance. The collaboration will leverage a secure infrastructure that is compliant with data privacy, information security, and regulatory concerns ...
In the complex landscape of medical waste management, the importance of effective treatment methods cannot be overstated. ...
Bergaust has extensive experience from jobs as financial manager in the medical click here to read full ...
Together, Tris Pharma and Perigon launched a direct-to-patient program, DYANAVEL Delivered, that allows patients and caregivers to seamlessly access DYANAVEL XR extended-release tablets through Perigon’s digital pharmacy, enhance their medication management, and receive reimbursement assistance and support to help navigate their treatment journey while ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
Manage your healthcare with the use of HEDIS (Healthcare Effectiveness Data and Information Set) and OMW (Osteoporosis Management in Women). ...
“With limited access to novel agents in these markets and with large populations, a high unmet medical need exists in management of both patients with MM and DLBCL. ...
Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wound. ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is scheduled to participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ...
From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making this important service convenient and accessible is key to improving health care quality and ...
– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...
Refractory epilepsy, referred to as uncontrolled, intractable, or drug-resistant epilepsy, occurs when medications do not bring seizures under control. Epilepsy patients that are refractory to oral anti-epileptic drug treatment have significantly higher mortality, higher morbidity, higher economic costs and diminished quality of life compared to those who suffer from epilepsy ...
He brings more than 20 years of experience in reimbursement, revenue cycle management, and contracting strategies that enhance collaboration and financial success. ...
We are very happy that our system is highly appreciated by medical staff and hospital management, but patients’ satisfaction who can safely participate in rehabilitation sessions at home is equally important to us. ...
– Company to Webcast Investor Event on September 30th at 8:00 p.m. ET – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment ...
Grafalon® has a solid clinical experience benefiting more than 250,000 patients and is a leader in many countries, changing the way that teams of transplant medical workers manage patient care and addressing a significant unmet need. ...